Tag Archives: gene

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Novartis beefs up its case for Zolgensma gene therapy ahead of FDA decision

Novartis is expecting the FDA to decide on its spinal muscular atrophy (SMA) gene therapy next month, but it’s already padding its case with new phase 3 data. And it’s data one executive hopes will quell some concerns raised about the therapy. For one thing, the numbers help address questions about whether the SMA treatment, dubbed… Read More »